Idera Pharmaceuticals Secures $19.5 Million in Funding; Proceeds to Fund Clinical Programs Targeting Toll-like Receptors
March 27 2006 - 8:30AM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) announced today that it has
raised $9.75 million in gross proceeds from the private placement
of common stock and warrants to new institutional investors, led by
Baker Brothers Investments and including Tang Capital Partners, LP,
and OrbiMed Advisors, LLC. The Company has also secured a
commitment to purchase up to $9.75 million of common stock from
Biotech Shares Ltd., an entity formed by several current long-term
Idera stockholders, supported by a letter of credit confirmed by
JPMorgan Chase Bank, N.A. The Company expects to use the proceeds
from the transactions to support the development of Idera's
pipeline of Toll-like receptor (TLR)-based drug candidates
including funding its ongoing Phase 2 trial of IMO-2055 in renal
cell cancer and its ongoing Phase 1/2 trial of IMO-2055 in
combination with chemotherapy in solid tumors, as well as the
pre-clinical development of a lead compound for infectious
diseases, IMO-2125. "We share Idera's long-term vision that
therapeutics targeted to Toll-like receptors may play an important
role across a broad range of therapeutic areas," said Julian Baker
of Baker Brothers Investments. "We look forward to the advancement
of the Company's pre-clinical and clinical pipeline of product
candidates in the coming years." "These financings provide Idera
with a strong financial footing to advance our clinical development
and drug discovery programs that are all derived from Idera's
proprietary approach to creating TLR-based therapeutics," said
Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief
Scientific Officer of Idera. "We are very pleased to have the
strong interest of new, well-respected biotechnology institutional
investors and the continued support of several current long-term
investors." About the Financings In connection with the private
placement with the new institutional investors, the Company issued,
for a purchase price of $9.75 million, 22,159,092 shares of its
common stock and warrants to purchase up to an aggregate of
16,619,319 shares of its common stock at an exercise price of $0.65
per share. The warrants are exercisable for a five-year period
beginning in September 2006. According to the terms of the
agreement, Idera has granted the investors certain participation
rights in future financings and Baker Brothers Investments the
right for a period of time to designate an individual for election
to the Board of Directors of Idera. In connection with its purchase
commitment, Biotech Shares Ltd. has agreed to purchase up to a
total of $9.75 million of common stock during the period from June
24, 2006 through December 31, 2006 in up to three drawdowns made by
Idera, at Idera's direction. In each drawdown, the shares of common
stock will be sold at a price equal to 80% of the volume weighted
average of the closing prices of the common stock on the five
trading days preceding the drawdown notice, but such purchase price
in no event will be less than the floor price of $0.64 per share,
which represents the closing price of the common stock on March 23,
2006. The Company's ability to make drawdowns is conditioned upon
the effectiveness of a registration statement covering the resale
of the shares to be issued and upon stockholder approval of an
increase in Idera's authorized common stock which Idera expects to
seek at its 2006 annual meeting. Biotech Shares Ltd's. commitment
to purchase the common stock is supported by a letter of credit
confirmed by JPMorgan Chase Bank, N.A. In connection with the
commitment to purchase common stock, Idera issued to Biotech Shares
Ltd. warrants to purchase up to 6,093,750 shares of common stock at
an exercise price of $0.74 per share. The warrants are exercisable
for a five-year period beginning in September 2006. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc. (AMEX: IDP) is a
Cambridge, Massachusetts-based biotechnology company focused on the
discovery, development, and commercialization of targeted immune
therapies based on modulation of Toll-like receptors (TLRs). Drug
candidates targeting TLRs have broad commercial potential in the
areas of oncology, infectious disease and allergy/asthma. Idera's
most advanced clinical candidate, IMO-2055 (or HYB2055), is an
agonist of TLR9 and is currently in a Phase 2 monotherapy trial in
renal cell carcinoma, and in a Phase 1/2 chemotherapy combination
therapy trial in solid tumors. Idera is collaborating with Novartis
for the discovery, optimization, development and commercialization
of TLR9 agonist drug candidates targeting TLR9 for asthma and
allergy. Idera also has selected another TLR9 agonist, IMO-2125, as
a lead candidate for infectious diseases. For more information,
visit www.iderapharma.com. Forward Looking Statements This press
release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology such as IMO-2055 will advance through the
clinical trial process on a timely basis or at all and receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether the Company will
complete enrollment of clinical trials in the time expected;
whether, if the Company's products such as IMO-2055 receive
approval, they will be successfully distributed and marketed;
whether Idera's cash resources will be sufficient to fund product
development and clinical trials; and such other important factors
as are set forth under the caption "Risk Factors" in Idera's
Quarterly Report on Form 10-Q filed on November 9, 2005, which
important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024